Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue

Author(s): Ludimila Cavalcante, David P. Kelsen and Kenneth H. Yu

Volume 20, Issue 42, 2014

Page: [6697 - 6701] Pages: 5

DOI: 10.2174/1381612820666140826154724

Price: $65

Abstract

Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.

Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy